1. Home
  2. TAC vs TWST Comparison

TAC vs TWST Comparison

Compare TAC & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransAlta Corporation

TAC

TransAlta Corporation

HOLD

Current Price

$12.94

Market Cap

3.5B

Sector

Utilities

ML Signal

HOLD

Logo Twist Bioscience Corporation

TWST

Twist Bioscience Corporation

HOLD

Current Price

$44.49

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TAC
TWST
Founded
1909
2013
Country
Canada
United States
Employees
1350
N/A
Industry
Electric Utilities: Central
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.0B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
TAC
TWST
Price
$12.94
$44.49
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
$23.67
$48.75
AVG Volume (30 Days)
1.3M
903.2K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
1.46%
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
N/A
$376,572,000.00
Revenue This Year
N/A
$18.91
Revenue Next Year
$2.24
$15.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
20.32
52 Week Low
$7.82
$23.30
52 Week High
$17.88
$57.88

Technical Indicators

Market Signals
Indicator
TAC
TWST
Relative Strength Index (RSI) 50.82 46.04
Support Level $12.08 $41.65
Resistance Level $13.94 $45.76
Average True Range (ATR) 0.45 2.66
MACD 0.05 -0.06
Stochastic Oscillator 76.04 26.56

Price Performance

Historical Comparison
TAC
TWST

About TAC TransAlta Corporation

TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse electrical power generation assets in Canada, the United States, and Western Australia. The company has reportable segments namely, Hydro, Wind & Solar, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

Share on Social Networks: